Anais Portalier
Overview
Explore the profile of Anais Portalier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
3
Citations
32
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ysebaert L, Ederhy S, Leblond V, Malartre S, Portalier A, Sibaud V, et al.
Clin Lymphoma Myeloma Leuk
. 2024 Nov;
25(3):e173-e181.
PMID: 39547859
Acalabrutinib, a second-generation Bruton's tyrosine kinase inhibitor (BTKi), offers an improved safety profile compared to first-generation inhibitors like ibrutinib. While BTKi guidelines exist, practical differences between BTKis-such as drug interactions...
2.
Blaize M, Thizy G, Boissonnas A, Portalier A, Lanternier F, Porte des Vaux C, et al.
Int J Infect Dis
. 2024 Mar;
142:107000.
PMID: 38461932
Objectives: Ibrutinib, a first-generation covalent Bruton's tyrosine kinase inhibitor (BTKi) was found to be a risk factor for the occurrence of invasive fungal complications. Acalabrutinib is a second-generation covalent BTKi...
3.
Blez D, Blaize M, Soussain C, Boissonnas A, Meghraoui-Kheddar A, Menezes N, et al.
Haematologica
. 2019 Jun;
105(2):478-489.
PMID: 31171644
The Bruton tyrosine kinase inhibitor ibrutinib has become a leading therapy against chronic lymphoid leukemia. Recently, ibrutinib has been associated with the occurrence of invasive fungal infections, in particular invasive...